Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105665523 | 10566552 | 3 | F | 2007 | 20160624 | 20141105 | 20160706 | EXP | PT-MYLANLABS-2014M1009098 | MYLAN | JOSE PEDRO ALMEIDA, ANABELA LOPES, MANUEL PEREIRA BARBOSA. REVISTA PORTUGUESA DE IMUNOALERGOLOGIA. OFFICIAL JOURNAL OF THE PORTUGUESE SOCIETY OF ALLERGOLOGY AND CLINICAL IMMUNOLOG. 2013;21:5 - 43 | 0.00 | Y | 0.00000 | 20160706 | OT | PT | PT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105665523 | 10566552 | 1 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Unknown | UNK | U | 0 | |||||||||
| 105665523 | 10566552 | 2 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | 40 MG, QD | U | 0 | 40 | MG | QD | |||||||
| 105665523 | 10566552 | 3 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 4 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | UNK | U | 0 | |||||||||
| 105665523 | 10566552 | 5 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 6 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 7 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 8 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 40 MG, UNK | U | 0 | 40 | MG | QD | ||||||
| 105665523 | 10566552 | 9 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 10 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 11 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | U | 90763 | ||||||||||
| 105665523 | 10566552 | 12 | SS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | U | 90763 | |||||||||||
| 105665523 | 10566552 | 13 | SS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | U | 90763 | |||||||||||
| 105665523 | 10566552 | 14 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | U | 0 | ||||||||||
| 105665523 | 10566552 | 15 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 16 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 17 | SS | ESOMEPRAZOLE | ESOMEPRAZOLE | 1 | Oral | U | 0 | ||||||||||
| 105665523 | 10566552 | 18 | SS | RABEPRAZOLE | RABEPRAZOLE | 1 | Oral | U | 0 | ||||||||||
| 105665523 | 10566552 | 19 | SS | RABEPRAZOLE | RABEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 20 | SS | RABEPRAZOLE | RABEPRAZOLE | 1 | U | 0 | |||||||||||
| 105665523 | 10566552 | 21 | C | DESLORATADINE. | DESLORATADINE | 1 | Unknown | 5 MG, QD | U | 0 | 5 | MG | QD | ||||||
| 105665523 | 10566552 | 22 | C | ACETYLSALICYLATE LYSINE | ASPIRIN DL-LYSINE | 1 | Intravenous (not otherwise specified) | UNK | U | 0 | |||||||||
| 105665523 | 10566552 | 23 | C | IBUPROFEN. | IBUPROFEN | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105665523 | 10566552 | 1 | Gastrooesophageal reflux disease |
| 105665523 | 10566552 | 2 | Prophylaxis |
| 105665523 | 10566552 | 3 | Influenza |
| 105665523 | 10566552 | 5 | Gastrooesophageal reflux disease |
| 105665523 | 10566552 | 6 | Influenza |
| 105665523 | 10566552 | 7 | Prophylaxis |
| 105665523 | 10566552 | 9 | Gastrooesophageal reflux disease |
| 105665523 | 10566552 | 10 | Prophylaxis |
| 105665523 | 10566552 | 12 | Gastrooesophageal reflux disease |
| 105665523 | 10566552 | 13 | Prophylaxis |
| 105665523 | 10566552 | 15 | Gastrooesophageal reflux disease |
| 105665523 | 10566552 | 16 | Prophylaxis |
| 105665523 | 10566552 | 19 | Gastrooesophageal reflux disease |
| 105665523 | 10566552 | 20 | Prophylaxis |
| 105665523 | 10566552 | 21 | Product used for unknown indication |
| 105665523 | 10566552 | 22 | Product used for unknown indication |
| 105665523 | 10566552 | 23 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105665523 | 10566552 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105665523 | 10566552 | Angioedema | |
| 105665523 | 10566552 | Drug hypersensitivity | |
| 105665523 | 10566552 | Erythema |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 105665523 | 10566552 | 1 | 2007 | 0 | ||
| 105665523 | 10566552 | 22 | 2007 | 0 |